Cranberry and enterocolitis in premature infants

Randomised analysis, double blind and controlled with placebo of the utility of the extract of cranberry in the prevention of the enterocolitis of premature infants

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN20343063

Enrollment

238

Registered

2011-04-06

Start date

2011-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Necrotising enterocolitis Pregnancy and Childbirth Necrotising enterocolitis of fetus and newborn

Interventions

1. Receive a dose of 0.5 ml of the prepared speech in the Pharmacy Department as unidosis in opaque vials. Opaque nasogastric administration every 12 hours. 2. (Placebo) - Receive a dose of 0.5 ml of

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Preterm infants less than 1800 g birth weight, either sex 2. Infants with gestational age less than 32 weeks (depending FUR)

Exclusion criteria

Exclusion criteria: 1. Newborns multiple malformations 2. Early neonatal sepsis 3. Does not provide consent to participate in the study

Design outcomes

Primary

Measure	Time frame
1. Enterocolitis 2. The follow-up of each patient is 1 month 3. The total test duration is 3 years	—

Secondary

Measure	Time frame
1. Poliphenols in urine 2. The follow-up of each patient is 1 month 3. The total test duration is 3 years	—

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026